Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress

Abstract

In recent years, more attention has been paid to the role of the glutamate transporter 1 (GLT-1, EAAT2) in major depressive disorder (MDD). However, experimental data on brain GLT-1 levels are, to some extent, inconsistent in human postmortem and animal studies. These discrepancies imply that the role of GLT-1 in the pathophysiology of MDD and the action of antidepressants remain obscure. This work was designed to study the impact of chronic unpredictable stress (CUS) for 2 sessions per day for 35 days and four weeks of fluoxetine (FLX) on depressive-like behaviors in rats, as well as the concomitant expression of the GLT-1 protein in the hippocampus. Behavioral changes were assessed by the sucrose preference and open field tests. GLT-1 levels were detected by immunohistchemistry and Western blot analysis. Our study demonstrated that the animals exposed to CUS showed depressive-like behaviors and exhibited a significant decrease in GLT-1 expression in the hippocampus. Chronic FLX treatment reversed the behavioral deficits and the CUS-induced decrease in GLT-1 levels. Taken together, our results support the reduction of GLT-1 in human postmortem studies in MDD and suggest that GLT-1 may be involved in the antidepressant activity of FLX. Our studies further support the notion that GLT-1 is an attractive candidate molecule associated with the fundamental processes of MDD and may be a potential, and novel pharmacological target for the treatment of MDD.

Keywords

chronic unpredictable stress / glutamate transporter 1 / glutamate / fluoxetine / hippocampus

References

[1] LicinioJ, WongML. Advances in depression research: 2011. Mol Psychiatry, 2011, 16(7): 686-687 PMID: 21697854

[2] DorisA, EbmeierK, ShajahanP. Depressive illness. Lancet, 1999, 354(9187): 1369-1375 PMID: 10533878

[3] MillanMJ. The role of monoamines in the actions of established and “novel” agents: a critical review. Eur J Pharmacol, 2004, 500(1–3): 371-384 PMID: 15464046

[4] TokitaK, YamajiT, HashimotoK. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav, 2012, 100(4): 688-704 PMID: 21536063

[5] SanacoraG, BanasrM. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry, 2013, 73(12): 1172-1179 PMCID: 3688253 PMID: 23726152

[6] LehreKP, levyLM, OttersenOP, et al. . Differential expression of two glial glutamate transporters in the rats brain: quantitative and immunocyochemical observations. J Neurosci, 1995, 15(3pt1): 1835-1853 PMID: 7891138

[7] RajkowskaG, Miguel-HidalgoJJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets, 2007, 6(3): 219-233 PMCID: 2918806 PMID: 17511618

[8] ChoudaryPV, MolnarM, EvansSJ, et al. . Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA, 2005, 102(43): 15 653-15 658

[9] ReaganLP, RosellDR, WoodGE, et al. . Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: Reversal by tianeptine. Proc Natl Acad Sci USA, 2004, 101(7): 2179-2184 PMCID: 357072 PMID: 14766991

[10] WoodGE, YoungLT, ReaganLP, et al. . Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment. Proc Natl Acad Sci USA, 2004, 101(11): 3973-3978 PMCID: 374354 PMID: 15001711

[11] ZinkM, VollmayrB, Gebicke-HaerterPJ, et al. . Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology, 2010, 58(2): 465-473 PMID: 19747495

[12] ZinkM, RappS, DonevR, et al. . Fluoxetine treatment induces EAAT2 expression in rat brain. J Neural Transm, 2011, 118(6): 849-855 PMID: 21161710

[13] BanasrM, ValentineGW, LiXY, et al. . Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry, 2007, 62(5): 496-504 PMID: 17585885

[14] YeY, WangG, WangH, et al. . Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett, 2011, 503(1): 15-19 PMID: 21843601

[15] GrippoAJ, BeltzTG, WeissRM, et al. . The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry, 2006, 59(4): 309-316 PMID: 16154542

[16] SurgetA, SaxeM, LemanS, et al. . Drug dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry, 2008, 64(4): 293-301 PMID: 18406399

[17] YangC, WangG, WangH, et al. . Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. Behav Brain Res, 2009, 205(2): 518-524 PMID: 19683020

[18] LiY, WangH, WangX, et al. . Differential expression of hippocampal EphA4 and ephrinA3 in anhedonic-like behavior, stress resilience, and antidepressant drug treatment after chronic unpredicted mild stress. Neurosci Lett, 2014, 566(30): 292-297 PMID: 24631563

[19] KanaiY, HedigerMA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arc, 2004, 447(5): 469-479

[20] BeartPM, O’SheaRD. Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement. Br J Pharmacol, 2007, 150(1): 5-17 PMCID: 2013845 PMID: 17088867

[21] CarboneM, DutyS, RattrayM. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int, 2012, 60(1): 31-38 PMCID: 3430367 PMID: 22080156

[22] ZarateCAJr, PayneJL, QuirozJ, et al. . An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry, 2004, 161(1): 171-174 PMID: 14702270

[23] ZarateCAJr, QuirozJA, SinghJB, et al. . An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry, 2005, 57(4): 430-432 PMID: 15705360

[24] SanacoraG, KendellSF, LevinY, et al. . Preliminary evidence of riluzole efficacy antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry, 2007, 61(6): 822-825 PMCID: 2754299 PMID: 17141740

[25] MillerTM, ClevelandDW. Medicine. Treating neurodegenerative diseases with antibiotics. Science, 2005, 307(5708): 361-362 PMID: 15661995

[26] RothsteinJD, PatelS, ReganMR, et al. . Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433(7021): 73-77 PMID: 15635412

[27] MineurYS, PicciottoMR, SanacoraG. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry, 2007, 61(2): 250-252 PMID: 16860779

[28] RaudenskyJ, YamamotoBK. Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function. Brain Res, 2007, 1135(1): 129-135 PMCID: 1839858 PMID: 17198685

[29] BanasrM, DumanRS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry, 2008, 64(10): 863-870 PMCID: 2709733 PMID: 18639237

[30] BanasrM, ChowdhuryGM, TerwilligerR, et al. . Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry, 2010, 15(5): 501-511 PMCID: 3347761 PMID: 18825147

[31] CzehB, SimonM, SchmeltingB, et al. . Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology, 2006, 31(8): 1616-1626 PMID: 16395301

[32] HughesEG, MaguireJL, McMinnMT, et al. . Loss of glial fibrillary acidic protein results in decreased glutamate transport and inhibition of PKA-induced EAAT2 cell surface trafficking. Brain Res Mol Brain Res, 2004, 124(2): 114-123 PMID: 15135219

[33] MaoQX, YangTD. Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res Bull, 2010, 81(4–5): 424-427 PMID: 19772901

[34] McEwenBS, ChattarjiS, DiamondDM, et al. . The neurobiological properties of Tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry, 2010, 15(3): 237-249 PMCID: 2902200 PMID: 19704408

[35] ThomeJ, SakaiN, ShinK, et al. . cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci, 2000, 20(11): 4030-4036 PMID: 10818138

[36] DanboltNC. Glutamate uptake. Prog Neurobiol, 2001, 65(1): 1-105 PMID: 11369436

[37] LeeY, GaskinsD, AnandA, et al. . Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology, 2007, 191(1): 55-65 PMID: 17225169

[38] Bechtholt-GompfAJ, WaltherHV, AdamsMA, et al. . Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology, 2010, 35(10): 2049-2059 PMCID: 3055299 PMID: 20531459

[39] JohnCS, SmithKL, Van’t VeerA, et al. . Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology, 2012, 37(11): 2467-2475 PMCID: 3442341 PMID: 22739467